Purpose: To assess the efficacy and tolerability of latanoprost in the treatment of glaucoma and ocular hypertension associated with Graves' ophthalmopathy. Prospective interventional case series.
Materials And Methods: 28 patients (19 females and 9 males) aged from 31 to 68 (mean age 45.5 +/- 5.6), presenting with diagnosis of Graves' ophthalmopathy and intraocular pressure equal to 25.0 mmHg or more. 18 Patients presented with inflammatory stage of Graves' ophthalmopathy. 22 patients were within the first two years from the onset of symptoms of Graves' ophthalmopathy. 6 patients had exophthalmos and history of active Graves' ophthalmopathy. Intraocular pressure was measured before treatment, and at two, four and six weeks of treatment with latanoprost at 9 am. Ocular symptoms and signs were noted before and after the treatment period.
Results: The mean baseline intraocular pressure was 26.6 +/- 2.5 mmHg, ranging from 25.0 mmHg to 42 mmHg. In two weeks of treatment, the mean intraocular pressure was 18.6 +/- 2.3 mmHg (min 12.0 mmHg, max 27.0 mmHg). At 4 weeks mean intraocular pressure was 18.4 +/- 2.2 mmHg (min 11.0 mmHg, max 28.0 mmHg). At 6 weeks mean intraocular pressure was 18.7 +/- 1.9 mmHg (ranging from 11 mmHg to 25.0 mmHg). 3 patients experienced mild side effects.
Conclusions: Latanoprost is effective and well tolerated in the treatment of increased intraocular pressure associated with Graves' ophthalmopathy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of preservative-free anti-glaucomatous eye drops (dorzolamide/timolol) in ocular hypertension and/or glaucoma.
Int Ophthalmol
January 2025
Chairman and Professor of Ophthalmology, Kasr Alainy Faculty of Medicine, Cairo University, Giza, Egypt.
Purpose: This study evaluated the efficacy, safety, and tolerability of a single-dose, preservative-free (PF) Dorzolamide/Timolol combination (Twinzol-SDU).
Methods: A 3-month single-arm, multicenter, prospective cohort study was conducted in Egypt between January 2021 and October 2022 on previously diagnosed and controlled patients with ocular hypertension and/or glaucoma. Efficacy was assessed using the change in intraocular pressure (IOP) after 6 and 12 weeks.
Factors associated with the time of glaucoma-related adverse events onset after pediatric cataract surgery and the preferred anti-glaucomatous surgical selection.
Int Ophthalmol
January 2025
Department of Ophthalmology and Visual Science, Eye and ENT Hospital, Shanghai Medical College, Fudan University, 83 Fenyang Road, Shanghai, 200031, China.
Purpose: To describe the clinical characteristics of glaucoma-related adverse events (GRAE) after pediatric cataract surgery. More importantly, to identify the factors associated with the time of GRAE onset and the preferred anti-glaucomatous surgical procedure for this disease.
Methods: Hospitalized medical records of patients who developed GRAE, which include glaucoma and glaucoma suspect, after pediatric cataract surgery (surgical age ≤ 14 years) between 1994 and 2021 were retrospectively reviewed.
Exploring the safety and feasibility of intracameral Aprokam® (cefuroxime sodium) in pediatric cataract surgery.
Int Ophthalmol
January 2025
Cleveland Clinic Abu Dhabi, Eye Institute, Abu Dhabi, United Arab Emirates.
Purpose: To describe the safety and assess the feasibility of using intracameral cefuroxime sodium (Aprokam®) during congenital cataract surgery as a preventive measure for endophthalmitis.
Design: Monocentric, prospective, observational pilot study.
Setting: San Giuseppe Hospital, University of Milan, Milan, Italy.
Since the trabecular meshwork (TM) is central to intraocular pressure (IOP) regulation and glaucoma, a deeper understanding of its genomic landscape is needed. We present a multimodal, single-cell resolution analysis of mouse limbal cells (includes TM). In total, we sequenced 9,394 wild-type TM cell transcriptomes.
View Article and Find Full Text PDFOutcomes of a non-diffractive extended depth of focus intraocular lens in patients with well-controlled glaucoma and ocular hypertension.
Int J Ophthalmol
January 2025
Department of Ophthalmology, University of Montreal, Quebec H3T 1J4, Canada.
Aim: To assess visual outcomes and satisfaction of a non-diffractive extended depth of focus (EDOF) intraocular lens (IOL) in individuals with ocular hypertension (OHT) and well-controlled mild glaucoma undergoing cataract surgery.
Methods: An investigator-initiated, single-center, prospective, interventional, noncomparative study conducted in Montreal, Canada. The study enrolled 31 patients (55 eyes) with OHT or mild glaucoma who received a non-diffractive EDOF IOL (Acrysof IQ Vivity).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!